RenovoRx secured the 10th position among medical device firms on a 2026 industry innovation list, highlighting its proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The accolade underscores the company’s advancement in targeted oncology drug delivery through its FDA-cleared RenovoCath device.

In its first full commercial year, RenovoRx recorded approximately $1.1 million in RenovoCath sales, driven by repeat orders from high-volume cancer centers. Adoption of the device within clinical workflows reflects growing physician interest in intra-arterial drug delivery as an alternative to systemic IV therapy.

RenovoRx projects an initial U.S. total addressable market of about $400 million in peak annual device sales, with multi-billion-dollar potential as TAMP expands into additional solid tumor indications. Ongoing efforts include partnerships and further revenue-generating activities to meet anticipated demand.